PPARγ agonists are known to improve insulin sensitization, modulate glucose and lipid metabolism [18], was also considered as candidate drug in the treatment of neurodegenerative disorders such as AD, Huntington’s disease, and Parkinson’s disease [19]–[21]. This evidence concerns the gene PPARG and Alzheimer disease.